Related Experiment Video

Updated: Feb 3, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

Galectin-3: A Novel Biomarker Predicts Sudden Cardiac Death in Hypertrophic Cardiomyopathy

Samim Emet1, Mubariz Dadashov1, Mehmet Rasih Sonsoz1

  • 1Department of Cardiology, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey.

The American Journal of the Medical Sciences
|October 22, 2018
PubMed

Insights

Serum galectin-3 levels correlate with sudden cardiac death risk in hypertrophic cardiomyopathy patients. This finding may help predict arrhythmia risk and guide prophylactic treatments.

Area of Science:

  • Cardiology
  • Biochemistry
  • Medical Diagnostics

Background:

  • Hypertrophic cardiomyopathy (HCM) is a primary cardiac condition causing left ventricular hypertrophy and potentially sudden cardiac death (SCD).
  • Galectin-3, a lectin linked to cardiac fibrosis and inflammation, is implicated in cardiovascular disease progression.

Purpose of the Study:

  • To investigate the association between serum galectin-3 levels and the 5-year sudden death risk criteria in patients with hypertrophic cardiomyopathy.
  • To evaluate galectin-3 as a potential biomarker for risk stratification in HCM.

Main Methods:

  • 52 patients with hypertrophic cardiomyopathy were assessed for 5-year SCD risk predictors based on 2014 European Society of Cardiology guidelines.
  • Serum galectin-3 levels were measured in all participants.
  • Statistical analysis was performed with a significance level of P < 0.05.

Main Results:

  • A significant correlation was identified between estimated 5-year SCD risk and serum galectin-3 levels in HCM patients.

Conclusions:

  • Serum galectin-3 may serve as a cost-effective biomarker for predicting arrhythmia risk in hypertrophic cardiomyopathy.
  • It could aid in determining antiarrhythmic prophylaxis and managing patients with implantable cardioverter-defibrillators.
Abstract

Keywords:
Galectin-3Hypertrophic cardiomyopathyRisk scoreSudden cardiac deathVentricular arrhythmias

More Related Videos

Complementation of Splicing Activity by a Galectin-3 - U1 snRNP Complex on Beads08:48

Complementation of Splicing Activity by a Galectin-3 - U1 snRNP Complex on Beads

Published on: December 9, 2020

2.5K
Large-Animal Model of Donation after Circulatory Death and Normothermic Regional Perfusion for Cardiac Assessment07:49

Large-Animal Model of Donation after Circulatory Death and Normothermic Regional Perfusion for Cardiac Assessment

Published on: May 10, 2022

2.0K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
490
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
862
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
568
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
538
Predicting Molecular Geometry02:27

Predicting Molecular Geometry

VSEPR Theory for Determination of Electron Pair Geometries
45.8K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
442